Mesothelioma in Louisiana

While mesothelioma is a problem in all states, the specific incident rate for Louisiana is 1.3 / 100,000. This is above the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in LA, recent LA mesothelioma-related court cases, mesothelioma specialists in LA and potential asbestos hotspots in Louisiana.

Louisiana Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of Louisiana

Louisiana Research and Clinical Trials

This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

Louisiana Doctors and Hospitals

This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

Louisiana Cases

This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.


Abstract: Malignant mesothelioma is a lung cancer originating from the pleura and is caused by occupational exposure to asbestos. Mesothelioma is highly overrepresented in South East Louisiana, specifically the New Orleans area. The city had a large shipyard industry and one of the largest asbestos manufacturing plants in the country; it has a disproportionately large incidence of this disease. There is no satisfactory treatment for this cancer and it is almost universally fatal, regardless of the stage of the tumor at the time of diagnosis. Current treatment modalities include surgery, chemotherapy, and radiation therapy, although in some series none of these modalities is superior to no treatment at all. Because of the dismal prognosis for patients with malignant mesothelioma, a new mode of treatment is desperately needed. A promising area of research into the treatment of various malignancies is gene therapy. Recent studies have demonstrated the utility of exposing tumor cells to cells transduced to express the Herpes simplex virus gene for thymidine kinase (HSV-TK). By virtue of their expression of HSV-TK, the transduced cells are rendered susceptible to the antiviral drug, ganciclovir (GCV). Nearby tumor cells are killed by a so-called bystander effect. In this protocol, we propose a Phase I trial to introduce HSV-TK transduced ovarian cancer cells into the pleural cavities of patients with malignant pleural mesothelioma, followed by systemic administration of ganciclovir. The hope is that administration of ganciclovir will result in killing of the transduced ovarian cancer cells as well as the nearby malignant mesothelioma cells. 

Tags: Cell Line, Gene Therapy, Human Therapy Evaluation, Mesothelioma, Neoplasm /cancer Therapy Clinical Trial Phase I, Clinical Trial Phase Ii /iii /iv Clinical Research, Human Subject 

  • Followup Grant: 5M01RR005096-090317
  • Followup Grant: 3M01RR005096-09S10317
  • Followup Grant: 5M01RR005096-120317
  • Followup Grant: 5M01RR005096-140317

Clinical Trials

Condition: Malignant Mesothelioma
Intervention: Biological: PA-1-STK ovarian carcinoma vaccine;   Drug: ganciclovir
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: erlotinib hydrochloride
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin;   Drug: gemcitabine hydrochloride
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: epirubicin hydrochloride;   Drug: gemcitabine hydrochloride
More Information

Condition: Mesothelioma;   Lung Cancer
Intervention: Drug: Comparator: Suberoylanilide Hydroxamic Acid (Vorinostat, MK0683);   Drug: Comparator: Placebo
More Information

Condition: Malignant Mesothelioma
Intervention: Biological: recombinant interferon alfa;   Drug: cisplatin;   Procedure: surgical procedure;   Radiation: radiation therapy
More Information

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
More Information

Hospital and Cancer Centers

We do not have any doctors or cancer centers for this state at the moment.

Rando v. Anco Insulations Inc.
No. 08-C-1163 C/w 08-C-1169, SUPREME COURT OF LOUISIANA, May 22, 2009, Decided
Cichirillo v. Avondale Indus.
No. 04-C-2894 C/w No. 04-C-2918 , SUPREME COURT OF LOUISIANA, November 29, 2005, Decided
Landry v. Avondale Indus.
Nos. 03-CC-3432, 03-CC-3434, 03-CC-3435 , SUPREME COURT OF LOUISIANA , July 2, 2004, Decided
Landry v. Avondale Indus.
No. 03-CC-0719 C/w No. 03-CC-0993 C/w No. 03-CC-1002 , SUPREME COURT OF LOUISIANA, December 3, 2003, Decided
Bonnette v. Conoco, Inc.
No. 2001-C-2767 , SUPREME COURT OF LOUISIANA, January 28, 2003, Decided
Estate of Patrick v. Bd. of Supervisors
No. 02-CC-2570 , SUPREME COURT OF LOUISIANA, November 22, 2002, Decided
Austin v. Abney Mills
No. 2001-C-1598 , SUPREME COURT OF LOUISIANA, September 4, 2002, Decided
Ruckstuhl v. Owens Corning Fiberglas Corp.
No. 98-CC-1126, SUPREME COURT OF LOUISIANA, April 13, 1999, Decided
Boudreaux v. Able Supply Co.
08-1350, COURT OF APPEAL OF LOUISIANA, THIRD CIRCUIT, October 7, 2009, Decided
Hymel v. Eagle, Inc.
NO. 2008-CA-1287, COURT OF APPEAL OF LOUISIANA, FOURTH CIRCUIT, March 19, 2009, Decided


If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:

  • This field is for validation purposes and should be left unchanged.

Get your free copy of
“Surviving Mesothelioma” Today!